Juvenile dermatomyositis (JDM) research hub

A clinical trial of Baricitinib in Juvenile Dermatomyositis (BAR-JDM): comparing baricitinib and steroids to methotrexate and steroids over 52 weeks

This study looks at a new treatment called baricitinib for children with a rare condition called juvenile dermatomyositis (JDM). It compares baricitinib plus steroids to the usual treatment (methotrexate plus steroids) to see if it's more effective and safer for newly diagnosed children.